Evercore

SkyTab Ranked as Top POS System for Customer Satisfaction in Independent Survey

Retrieved on: 
вторник, марта 12, 2024
Software, Technology, Electronic Commerce, Payments, POS, Multimedia, Restaurant, Sale, Evercore, Retail

In a recent independent survey conducted by leading Wall Street equity research firm Evercore ISI , SkyTab was ranked first in customer satisfaction among restaurant point-of-sale (POS) system providers.

Key Points: 
  • In a recent independent survey conducted by leading Wall Street equity research firm Evercore ISI , SkyTab was ranked first in customer satisfaction among restaurant point-of-sale (POS) system providers.
  • Powered by Shift4 (NYSE: FOUR), SkyTab POS is a modern, all-in-one restaurant technology platform designed to streamline operations, simplify business management, and improve the guest experience.
  • View the full release here: https://www.businesswire.com/news/home/20240312170988/en/
    SkyTab POS System & SkyTab Mobile (Graphic: Business Wire)
    The proprietary survey included over 200 owners and operators of restaurants across the United States.
  • SkyTab earned a score of 4.29 out of 5.0 for customer satisfaction, ranking above competitors Toast, Clover, and Square.

Kingswood U.S. Accelerates Expansion of Successful In-house Investment Banking Group with Appointment of Four New Members

Retrieved on: 
понедельник, апреля 1, 2024
Wheaton College, Nomura Securities, Partner (business rank), Business, Acquisition, Columbia University, University, Head, Evercore, Investment banking, Capital market, International finance, Vice, Citco, UBS, RBC Capital Markets, Security (finance)

NEW YORK, April 1, 2024 /PRNewswire/ -- Kingswood U.S., part of a network of independent wealth management firms that oversees more than $14 billion in client assets globally, today announced the appointment of four new members to its Investment Banking team. Braden Ferrari has been brought on as Head of Institutional Sales, David Braccia and Evan Wynn join as Vice Presidents, Capital Markets and Jacob Wilson has been named a Vice Presidents, Investment Banking.

Key Points: 
  • The significant expansion of the Kingswood Investments team follows the strategic buildout of the firm's in-house investment banking capabilities over the past few years and illustrates the firm's commitment to this successful and growing business.
  • The Kingswood U.S. investment banking group provides access to capital to mid-market businesses undergoing varying degrees of operational, financial or market-driven change.
  • Braden Ferrari has over 20 years of corporate finance and investment banking experience, advising C-level executives and the boards of directors at public companies.
  • The Kingswood Investment Banking team is comprised of senior professionals with an average of more than 20 years in investment banking, located in New York, Florida and Texas.

Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in Amylyx Pharmaceuticals, Inc. (AMLX) Securities Class Action

Retrieved on: 
понедельник, марта 11, 2024
Court, ALS, District court, AMX0035, Patient, IBD, Evercore, Amyotrophy, Pharmaceutical industry

Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis (“ALS”) and other neurodegenerative diseases.
  • The Company’s products include, among others, AMX0035 (commercially referred to as “RELYVRIO” in the U.S.), for the treatment of ALS.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
суббота, марта 9, 2024
Uber, News, Neurobiology of Aging, Form, Apoptosis, IPO, Health, Particulates, Cassava Sciences, City University, P.C, Electrode, ALS, Register, Initiative, Cassava, AMX0035, Journal, Graphite, IBD, Evercore, EAF, Amyotrophy, Environment, DoorDash, Complaint, Safety, Biomarker, Public expenditure, Sustainable development, Amylyx Pharmaceuticals, Science, Prescription, Prospectus, GrafTech, Reuters, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Government, Patient, Cognition, Defendant, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
пятница, марта 8, 2024
Varick Street, Attention, SAN, Jefferies Group, Prospectus, Telephone, 2nd Floor, Åkerö, Sale, Exercise, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.

Key Points: 
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.
  • J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI acted as joint book-running managers for the offering.
  • The shares of common stock were offered by Akero pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).
  • A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on March 6, 2024.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
четверг, марта 7, 2024
Pomerantz, Court, ALS, Person, Prior, Food, Complaint, District court, Apoptosis, Ext, AMX0035, Patient, LLP, IBD, Evercore, Action Replay, Amyotrophy, Prescription, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
четверг, марта 7, 2024
Court, BBC World Service, Advertising, Investor's Business Daily, Patient, Amylyx Pharmaceuticals, LLP, IBD, Evercore, Prescription, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Viper Energy Announces Pricing of Secondary Common Stock Offering by Diamondback Energy, Inc.

Retrieved on: 
среда, марта 6, 2024
Attention, Goldman Sachs, J.P. Morgan & Co., TPH, Telephone, Scotiabank, Sale, Perella Weinberg Partners, Equity capital markets, Form, Broadridge Financial Solutions, BofA Securities, Roth Capital Partners, Security (finance), Evercore, Barclays, Form S-3

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).

Key Points: 
  • MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).
  • The Secondary Offering is expected to close on March 8, 2024, subject to customary closing conditions.
  • J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.
  • The Secondary Offering may only be made by means of a prospectus supplement and related base prospectus.

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on: 
среда, марта 6, 2024
Varick Street, Attention, SAN, Jefferies Group, J.P. Morgan & Co., Prospectus, Telephone, 2nd Floor, Sale, Exercise, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.
  • All of the shares in the offering are being offered by Akero Therapeutics.
  • In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The shares of common stock are being offered by Akero Therapeutics pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).

Viper Energy Launches Secondary Common Stock Offering By Diamondback Energy, Inc.

Retrieved on: 
вторник, марта 5, 2024
Attention, Goldman Sachs, J.P. Morgan & Co., Telephone, Sale, Equity capital markets, Form, Broadridge Financial Solutions, Security (finance), Evercore, Barclays, Form S-3

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten public offering of 11,500,000 shares of its Class A common stock by Viper’s parent, Diamondback Energy, Inc. (the “Selling Stockholder”), subject to market and other conditions (the “Secondary Offering”).

Key Points: 
  • MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten public offering of 11,500,000 shares of its Class A common stock by Viper’s parent, Diamondback Energy, Inc. (the “Selling Stockholder”), subject to market and other conditions (the “Secondary Offering”).
  • Viper will not receive any proceeds from the sale of the shares by the Selling Stockholder.
  • The Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of Viper’s Class A common stock.
  • J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.